Highlights Outlook Therapeutics, Inc.

Equities

OTLK

US69012T3059

Real-time Estimate Cboe BZX Other stock markets 15:21:23 2024-05-16 EDT			5-day change	1st Jan Change
7.2 ^USD	-3.10%		-6.60%	-8.38%

05-15	Outlook Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI
05-13	Outlook Therapeutics Submits Marketing Application for Wet Age-related Macular Degeneration Therapy in UK	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Outlook Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	05-15	CI
Outlook Therapeutics Submits Marketing Application for Wet Age-related Macular Degeneration Therapy in UK	05-13	MT
North American Morning Briefing : Stocks Set for -2-	03-28	DJ
Outlook Therapeutics Reports Secondary Share Offering	03-25	MT
Sector Update: Health Care Stocks Ease Late Afternoon	03-22	MT
Sector Update: Health Care Stocks Ease Friday Afternoon	03-22	MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday	03-22	MT
Outlook Therapeutics Gets EMA Panel Positive Opinion for Wet AMD Treatment -- Shares Rise Pre-Bell	03-22	MT
Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	03-22	CI
Outlook Therapeutics to Begin Reverse Stock Split for Regaining Nasdaq Compliance	03-12	MT
North American Morning Briefing : S&P 500 Seen -2-	02-16	DJ
Outlook Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	02-14	CI
Outlook Therapeutics, Inc. Doses First Subject in Norse Eight	01-31	CI
North American Morning Briefing : Intel Drags Down -2-	01-26	DJ
Outlook Therapeutics Says FDA Clarifies Steps for ONS-5010 Study, Enters Securities Purchase Deals	01-23	MT
Outlook Therapeutics Shares Rally Premarket on ONS-5010 Advances	01-23	DJ
Outlook Therapeutics Receives FDA Agreement under Special Protocol Assessment for 90 Day Non-Inferiority Study, NORSE EIGHT	01-23	CI
North American Morning Briefing : S&P 500 Futures Just Shy of Record High	12-28	DJ
Outlook Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	12-22	CI
Outlook Therapeutics, Inc. Submits Special Protocol Assessment to FDA for Non-Inferiority Study of ONS-5010	12-19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Outlook Therapeutics, Inc.

Equities

OTLK

US69012T3059

Highlights

Filters